Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.


BACKGROUND Resistance to direct-acting antivirals represents a new challenge in the treatment of chronic hepatitis C. METHODS SPRINT-1 was a randomized study of treatment-naive patients with genotype (G) 1 hepatitis C infection (n=595) that evaluated the safety and efficacy of boceprevir (BOC) when added to pegylated interferon-α2b plus ribavirin (PR… (More)
DOI: 10.3851/IMP2549